Aplagon Closes Oversubscribed EUR 2.2M Funding Round

HELSINKI, May 28, 2021. Aplagon Oy (“Aplagon”), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic compounds to treat vascular injury related blood vessel occlusions and tissue damage, today announced the closing of a EUR 2.2 million funding round. The fundraise was arranged in collaboration with Invesdor Group and was oversubscribed.

These funds increase the total equity investments and Business Finland R&D-loans so far raised by Aplagon to EUR 11.5 million. The majority of the raise will be used to fund planned clinical studies, including a Phase 1/2a study in end-stage chronic kidney disease patients undergoing vascular access surgery for dialysis, a Phase 1 study in healthy volunteers, and a Phase 2 study in patients suffering from COVID-19-induced coagulopathy. The studies will be performed in India in collaboration with Aplagon’s local partner, Cadila Pharmaceuticals Ltd.

Aki Prihti, CEO of Aplagon, said: “We are extremely pleased with the successful closing of the funding round and the strong interest shown by investors. The funds raised will enable us to move forward with planned clinical studies of our APAC therapeutics with the goal of demonstrating their preliminary safety and efficacy in our initial target indications. We would like to thank our existing investors for their continued support and welcome our new investors as shareholders in Aplagon”.

Aplagon’s APACs are first-in-class antithrombotic compounds with-vasculoprotective effects, for the management of vascular injury related blood vessel occlusions and tissue damage. The compounds are named after their unique dual antiplatelet (AP) and anticoagulant (AC) activity. They actively target vascular injury sites where they provide local long-term antithrombotic and anti-inflammatory protection without a prolonged systemic effect, thereby also reducing the bleeding risks associated with systemic antithrombotics. The initial target indications for APACs include hemodialysis access failure, COVID-19/sepsis-induced coagulopathy, and peripheral arterial disease.

– Ends –

About Aplagon Oy (www.aplagon.com)
Aplagon Oy is a pharmaceutical discovery and development company, based in Helsinki, Finland, developing proprietary locally acting vasculoprotective antithrombotic products (APACs) for the management of vascular injury related blood vessel occlusions and tissue damage.

Aplagon has a strong network of collaborators among top scientists and laboratories in Europe and the US in the field of vascular medicine and is backed by leading Finnish life science investors. Aplagon is partnered with Cadila Pharmaceuticals Ltd, one of the largest privately owned pharmaceutical companies in India, for the clinical development and commercialisation of APAC in India.

Aplagon was founded in 2009 and is based on the pioneering research performed by Prof. Riitta Lassila and associates at Wihuri Research Institute in Helsinki, Finland on mast cell-derived heparin proteoglycans. Aplagon owns all Intellectual Property rights to the APAC molecule.

For further information, please contact:

Aplagon Oy Instinctif Partners
At the Company:
Aki Prihti, CEO
Tel. +358-40-762 5159
Media enquiries:
Melanie Toyne-Sewell / Katie Duffell
Instinctif Partners
Tel: +44 20 7457 2013